Home » Stocks » JAN

JanOne Inc. (JAN)

Stock Price: $6.97 USD -0.73 (-9.48%)
Updated May 7, 2021 4:00 PM EDT - Market closed
Market Cap 16.75M
Revenue (ttm) 33.87M
Net Income (ttm) -8.50M
Shares Out 1.85M
EPS (ttm) -3.95
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 7
Last Price $6.97
Previous Close $7.70
Change ($) -0.73
Change (%) -9.48%
Day's Open 7.52
Day's Range 6.87 - 7.67
Day's Volume 241,949
52-Week Range 2.26 - 31.83

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

LAS VEGAS, Feb. 2, 2021 /PRNewswire/ -- JanOne Inc. (Nasdaq: JAN), a company focused on developing treatments for conditions that cause severe pain and drugs with non-addictive, pain-relieving propertie...

3 months ago - PRNewsWire

LAS VEGAS, Jan. 29, 2021 /PRNewswire/ -- JanOne Inc. (NASDAQ: JAN), a company focused on developing treatments for conditions that cause severe pain and drugs with non-addictive, pain-relieving properti...

3 months ago - PRNewsWire

JanOne (NASDAQ: JAN) shares are trading higher as speculative retail trading, particularly among the Reddit community, continues to drive volatility in the stock. JanOne is focused on reducing opioid ad...

3 months ago - Benzinga

JanOne (JAN) stock is soaring higher Thursday morning as it joins other stocks being boosted by Reddit and other social media users. The post JAN Stock: JanOne Shares Skyrocket as Part of Reddit Run-Up ...

3 months ago - InvestorPlace

LAS VEGAS, Sept. 22, 2020 /PRNewswire/ -- JanOne Inc. (Nasdaq: JAN), a company focused on developing treatments for conditions that cause severe pain and drugs with non-addictive, pain-relieving propert...

7 months ago - PRNewsWire

LAS VEGAS, Sept. 16, 2020 /PRNewswire/ -- JanOne Inc.

7 months ago - PRNewsWire

JanOne Inc. (JAN) CEO Tony Isaac on Drug Candidate JAN101 - Telebriefing and Corporate Update Call Transcript

8 months ago - Seeking Alpha

LAS VEGAS, Aug. 19, 2020 /PRNewswire/ -- JanOne Inc.

8 months ago - PRNewsWire

LAS VEGAS, Aug. 4, 2020 /PRNewswire/ -- JanOne Inc.

9 months ago - PRNewsWire

LAS VEGAS, July 30, 2020 /PRNewswire/ -- JanOne Inc. (NASDAQ:JAN), a company focused on finding treatments for conditions that cause severe pain and bringing to market drugs and therapies with non-addic...

9 months ago - PRNewsWire

LAS VEGAS, July 8, 2020 /PRNewswire/ -- JanOne Inc. (NASDAQ:JAN), a company focused on finding treatments for conditions that cause severe pain and bringing to market drugs and therapies with non-addict...

10 months ago - PRNewsWire

LAS VEGAS, June 30, 2020 /PRNewswire/ -- JanOne Inc. (NASDAQ:JAN), a company focused on finding treatments for conditions that cause severe pain and bringing to market drugs and therapies with non-addic...

10 months ago - PRNewsWire

LAS VEGAS, June 25, 2020 /PRNewswire/ -- JanOne Inc. (NASDAQ: JAN), a company focused on bringing treatments to market for conditions that cause severe pain and drugs with non-addictive pain relieving p...

10 months ago - PRNewsWire

About JAN

JanOne Inc., a clinical-stage biopharmaceutical company, focuses on identifying, acquiring, licensing, developing, partnering, and commercializing novel, non-opioid, and non-addictive therapies to address the unmet medical need for the treatment of pain. It operates in three segments: Biotechnology, Recycling, and Technology. The company's lead product candidate is JAN101, a patented oral and sustained release pharmaceutical composition of sodium nitrite that targets poor blood flow to the extremities in patients with diabetes or peripheral art... [Read more...]

Industry
Waste Management
Founded
1976
Stock Exchange
NASDAQ
Ticker Symbol
JAN
Full Company Profile

Financial Performance

In 2020, JanOne's revenue was $33.87 million, a decrease of -3.50% compared to the previous year's $35.10 million. Losses were -$8.50 million, -28.97% less than in 2019.

Financial Statements

Analyst Forecasts

The average 12-month stock price forecast for JanOne is 4.00, which is a decrease of -42.61% from the latest price.

Price Target
$4.00
(-42.61% downside)